AU2019387494A1 - Methods for dosing and treatment of B cell malignancies in adoptive cell therapy - Google Patents

Info

Publication number

AU2019387494A1

AU2019387494A1 AU2019387494A AU2019387494A AU2019387494A1 AU 2019387494 A1 AU2019387494 A1 AU 2019387494A1 AU 2019387494 A AU2019387494 A AU 2019387494A AU 2019387494 A AU2019387494 A AU 2019387494A AU 2019387494 A1 AU2019387494 A1 AU 2019387494A1

Authority

AU

Australia

Prior art keywords

cells

subject

car

dose

administration

Prior art date

2018-11-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 358
• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 64
• 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 17
• 230000036210 malignancy Effects 0.000 title claims abstract description 17
• 238000011282 treatment Methods 0.000 title claims description 236
• 238000011467 adoptive cell therapy Methods 0.000 title abstract description 20
• 210000004027 cell Anatomy 0.000 claims abstract description 506
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 360
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims abstract description 192
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims abstract description 179
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 135
• 238000002560 therapeutic procedure Methods 0.000 claims abstract description 130
• 201000010099 disease Diseases 0.000 claims abstract description 119
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims abstract description 100
• 108020003175 receptors Proteins 0.000 claims abstract description 74
• 102000005962 receptors Human genes 0.000 claims abstract description 73
• 238000004519 manufacturing process Methods 0.000 claims abstract description 51
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 404
• 238000002659 cell therapy Methods 0.000 claims description 205
• 239000003795 chemical substances by application Substances 0.000 claims description 198
• 239000000203 mixture Substances 0.000 claims description 189
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 155
• 230000007135 neurotoxicity Effects 0.000 claims description 145
• 206010044221 Toxic encephalopathy Diseases 0.000 claims description 144
• 231100000228 neurotoxicity Toxicity 0.000 claims description 144
• 206010029350 Neurotoxicity Diseases 0.000 claims description 141
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 129
• 206010052015 cytokine release syndrome Diseases 0.000 claims description 122
• 239000012472 biological sample Substances 0.000 claims description 89
• 230000004044 response Effects 0.000 claims description 88
• 230000001988 toxicity Effects 0.000 claims description 88
• 231100000419 toxicity Toxicity 0.000 claims description 88
• 206010037660 Pyrexia Diseases 0.000 claims description 75
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 68
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 66
• 230000002829 reductive effect Effects 0.000 claims description 60
• 238000011161 development Methods 0.000 claims description 59
• 230000018109 developmental process Effects 0.000 claims description 59
• LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 56
• 229960001183 venetoclax Drugs 0.000 claims description 56
• 239000003112 inhibitor Substances 0.000 claims description 50
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 49
• 239000000427 antigen Substances 0.000 claims description 44
• 108091007433 antigens Proteins 0.000 claims description 44
• 102000036639 antigens Human genes 0.000 claims description 44
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 43
• 229960001507 ibrutinib Drugs 0.000 claims description 43
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 43
• 208000024891 symptom Diseases 0.000 claims description 42
• 101800003050 Interleukin-16 Proteins 0.000 claims description 40
• 201000011510 cancer Diseases 0.000 claims description 39
• 230000000977 initiatory effect Effects 0.000 claims description 37
• 229940125814 BTK kinase inhibitor Drugs 0.000 claims description 35
• 208000007660 Residual Neoplasm Diseases 0.000 claims description 35
• -1 Foetal AchR Proteins 0.000 claims description 34
• 230000011664 signaling Effects 0.000 claims description 27
• 230000002459 sustained effect Effects 0.000 claims description 27
• 210000004369 blood Anatomy 0.000 claims description 26
• 239000008280 blood Substances 0.000 claims description 26
• 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 25
• 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 25
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 22
• 230000001754 anti-pyretic effect Effects 0.000 claims description 22
• 229960004397 cyclophosphamide Drugs 0.000 claims description 22
• 229960000390 fludarabine Drugs 0.000 claims description 22
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 22
• 239000002221 antipyretic Substances 0.000 claims description 21
• 208000032839 leukemia Diseases 0.000 claims description 20
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 19
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 19
• 239000003153 chemical reaction reagent Substances 0.000 claims description 19
• 230000027455 binding Effects 0.000 claims description 17
• 229960003957 dexamethasone Drugs 0.000 claims description 14
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 14
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 13
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 13
• 210000002966 serum Anatomy 0.000 claims description 13
• 125000006850 spacer group Chemical group 0.000 claims description 12
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 10
• 208000031404 Chromosome Aberrations Diseases 0.000 claims description 10
• 230000000139 costimulatory effect Effects 0.000 claims description 10
• 108090000623 proteins and genes Proteins 0.000 claims description 10
• 229960004641 rituximab Drugs 0.000 claims description 10
• 206010025323 Lymphomas Diseases 0.000 claims description 9
• 150000003431 steroids Chemical class 0.000 claims description 9
• 238000002648 combination therapy Methods 0.000 claims description 8
• 230000001086 cytosolic effect Effects 0.000 claims description 8
• 239000000523 sample Substances 0.000 claims description 8
• 229960003989 tocilizumab Drugs 0.000 claims description 8
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 7
• 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 7
• 230000035772 mutation Effects 0.000 claims description 7
• 108700012439 CA9 Proteins 0.000 claims description 6
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 6
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 6
• 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 6
• 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 6
• 210000002381 plasma Anatomy 0.000 claims description 6
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 5
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 5
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 5
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 5
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
• 208000025316 Richter syndrome Diseases 0.000 claims description 5
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
• 238000001959 radiotherapy Methods 0.000 claims description 5
• 238000012384 transportation and delivery Methods 0.000 claims description 5
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
• 108010058905 CD44v6 antigen Proteins 0.000 claims description 4
• 101150029707 ERBB2 gene Proteins 0.000 claims description 4
• 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
• 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 4
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 4
• 101001095088 Homo sapiens Melanoma antigen preferentially expressed in tumors Proteins 0.000 claims description 4
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 4
• 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 claims description 4
• 102000003735 Mesothelin Human genes 0.000 claims description 4
• 108090000015 Mesothelin Proteins 0.000 claims description 4
• 102100034256 Mucin-1 Human genes 0.000 claims description 4
• 108010008707 Mucin-1 Proteins 0.000 claims description 4
• 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 4
• 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 4
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
• 208000008383 Wilms tumor Diseases 0.000 claims description 4
• 208000026448 Wilms tumor 1 Diseases 0.000 claims description 4
• 102100022748 Wilms tumor protein Human genes 0.000 claims description 4
• 101710127857 Wilms tumor protein Proteins 0.000 claims description 4
• 235000001014 amino acid Nutrition 0.000 claims description 4
• 150000001413 amino acids Chemical class 0.000 claims description 4
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
• 235000018417 cysteine Nutrition 0.000 claims description 4
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
• 244000052769 pathogen Species 0.000 claims description 4
• 230000001717 pathogenic effect Effects 0.000 claims description 4
• GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 3
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
• 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 3
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
• 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims description 3
• 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims description 3
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
• 239000000539 dimer Substances 0.000 claims description 3
• 238000003018 immunoassay Methods 0.000 claims description 3
• 229940043355 kinase inhibitor Drugs 0.000 claims description 3
• 239000003446 ligand Substances 0.000 claims description 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
• 229920001184 polypeptide Polymers 0.000 claims description 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
• 229960003323 siltuximab Drugs 0.000 claims description 3
• 238000012360 testing method Methods 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 239000004475 Arginine Substances 0.000 claims description 2
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
• 102100032912 CD44 antigen Human genes 0.000 claims description 2
• 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
• 102000016736 Cyclin Human genes 0.000 claims description 2
• 108050006400 Cyclin Proteins 0.000 claims description 2
• 108010060273 Cyclin A2 Proteins 0.000 claims description 2
• 102100025191 Cyclin-A2 Human genes 0.000 claims description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 2
• 239000004471 Glycine Substances 0.000 claims description 2
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
• 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 2
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
• 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 2
• 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 2
• 108060003951 Immunoglobulin Proteins 0.000 claims description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
• 102100023123 Mucin-16 Human genes 0.000 claims description 2
• 241001529936 Murinae Species 0.000 claims description 2
• 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 2
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
• 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
• 108010002687 Survivin Proteins 0.000 claims description 2
• 102100035721 Syndecan-1 Human genes 0.000 claims description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
• 239000004473 Threonine Chemical group 0.000 claims description 2
• 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 2
• 108091008605 VEGF receptors Proteins 0.000 claims description 2
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
• 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
• 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims description 2
• 230000003432 anti-folate effect Effects 0.000 claims description 2
• 229940127074 antifolate Drugs 0.000 claims description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
• 230000009977 dual effect Effects 0.000 claims description 2
• 108010038795 estrogen receptors Proteins 0.000 claims description 2
• 230000001605 fetal effect Effects 0.000 claims description 2
• 229940014144 folate Drugs 0.000 claims description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 2
• 235000019152 folic acid Nutrition 0.000 claims description 2
• 239000011724 folic acid Substances 0.000 claims description 2
• 239000004052 folic acid antagonist Substances 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 102000018358 immunoglobulin Human genes 0.000 claims description 2
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
• 210000004986 primary T-cell Anatomy 0.000 claims description 2
• 102000003998 progesterone receptors Human genes 0.000 claims description 2
• 108090000468 progesterone receptors Proteins 0.000 claims description 2
• 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 2
• 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 2
• 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 2
• 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
• 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
• 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
• 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
• 101150047061 tag-72 gene Proteins 0.000 claims 2
• 102100038595 Estrogen receptor Human genes 0.000 claims 1
• 101150032879 Fcrl5 gene Proteins 0.000 claims 1
• 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
• 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims 1
• 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
• 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
• 238000011321 prophylaxis Methods 0.000 abstract description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 106
• 230000000694 effects Effects 0.000 description 53
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 41
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 41
• 210000001185 bone marrow Anatomy 0.000 description 39
• 230000002025 microglial effect Effects 0.000 description 39
• 238000002347 injection Methods 0.000 description 30
• 239000007924 injection Substances 0.000 description 30
• 102000049772 Interleukin-16 Human genes 0.000 description 29
• 150000003839 salts Chemical class 0.000 description 27
• 102000004127 Cytokines Human genes 0.000 description 25
• 108090000695 Cytokines Proteins 0.000 description 25
• 239000003814 drug Substances 0.000 description 24
• 239000003246 corticosteroid Substances 0.000 description 20
• 210000000274 microglia Anatomy 0.000 description 19
• 239000000090 biomarker Substances 0.000 description 18
• 150000001875 compounds Chemical class 0.000 description 17
• 238000009169 immunotherapy Methods 0.000 description 17
• 208000035475 disorder Diseases 0.000 description 16
• 229940124597 therapeutic agent Drugs 0.000 description 16
• 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 14
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 14
• 238000000684 flow cytometry Methods 0.000 description 14
• 239000003862 glucocorticoid Substances 0.000 description 14
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 13
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 13
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 13
• 230000020411 cell activation Effects 0.000 description 13
• 238000001802 infusion Methods 0.000 description 13
• 230000004083 survival effect Effects 0.000 description 13
• 230000001225 therapeutic effect Effects 0.000 description 13
• 108090001005 Interleukin-6 Proteins 0.000 description 12
• 102000004889 Interleukin-6 Human genes 0.000 description 12
• 229940100601 interleukin-6 Drugs 0.000 description 12
• 208000037821 progressive disease Diseases 0.000 description 12
• 230000001976 improved effect Effects 0.000 description 11
• 108010074051 C-Reactive Protein Proteins 0.000 description 10
• 102100032752 C-reactive protein Human genes 0.000 description 10
• 208000001953 Hypotension Diseases 0.000 description 10
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 10
• 230000036543 hypotension Effects 0.000 description 10
• 231100000331 toxic Toxicity 0.000 description 10
• 230000002588 toxic effect Effects 0.000 description 10
• 206010010904 Convulsion Diseases 0.000 description 9
• 108010074328 Interferon-gamma Proteins 0.000 description 9
• 102000008070 Interferon-gamma Human genes 0.000 description 9
• 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 9
• 229960003130 interferon gamma Drugs 0.000 description 9
• 210000004698 lymphocyte Anatomy 0.000 description 9
• 210000005259 peripheral blood Anatomy 0.000 description 9
• 239000011886 peripheral blood Substances 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
• 239000008194 pharmaceutical composition Substances 0.000 description 8
• 150000003384 small molecules Chemical class 0.000 description 8
• 229940124291 BTK inhibitor Drugs 0.000 description 7
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
• 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 7
• 102000003814 Interleukin-10 Human genes 0.000 description 7
• 108090000174 Interleukin-10 Proteins 0.000 description 7
• 230000002411 adverse Effects 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 229940076144 interleukin-10 Drugs 0.000 description 7
• 229960005489 paracetamol Drugs 0.000 description 7
• 230000036961 partial effect Effects 0.000 description 7
• 230000002085 persistent effect Effects 0.000 description 7
• 238000003752 polymerase chain reaction Methods 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 230000008685 targeting Effects 0.000 description 7
• 102000006306 Antigen Receptors Human genes 0.000 description 6
• 108010083359 Antigen Receptors Proteins 0.000 description 6
• 238000011357 CAR T-cell therapy Methods 0.000 description 6
• 206010060860 Neurological symptom Diseases 0.000 description 6
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 6
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 6
• 238000004820 blood count Methods 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• 231100000517 death Toxicity 0.000 description 6
• 238000012350 deep sequencing Methods 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 210000001165 lymph node Anatomy 0.000 description 6
• 230000003211 malignant effect Effects 0.000 description 6
• 238000007481 next generation sequencing Methods 0.000 description 6
• 230000002688 persistence Effects 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
• 108010082126 Alanine transaminase Proteins 0.000 description 5
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
• 108010002350 Interleukin-2 Proteins 0.000 description 5
• 102000000588 Interleukin-2 Human genes 0.000 description 5
• 208000008771 Lymphadenopathy Diseases 0.000 description 5
• 108091008874 T cell receptors Proteins 0.000 description 5
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
• 230000000735 allogeneic effect Effects 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 230000014509 gene expression Effects 0.000 description 5
• 208000018555 lymphatic system disease Diseases 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 238000010837 poor prognosis Methods 0.000 description 5
• 238000011084 recovery Methods 0.000 description 5
• 229940037128 systemic glucocorticoids Drugs 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• BNVPFDRNGHMRJS-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 BNVPFDRNGHMRJS-UHFFFAOYSA-N 0.000 description 4
• 208000014644 Brain disease Diseases 0.000 description 4
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
• 102000019034 Chemokines Human genes 0.000 description 4
• 108010012236 Chemokines Proteins 0.000 description 4
• 102000001301 EGF receptor Human genes 0.000 description 4
• 108060006698 EGF receptor Proteins 0.000 description 4
• 208000032274 Encephalopathy Diseases 0.000 description 4
• 208000002633 Febrile Neutropenia Diseases 0.000 description 4
• 206010019233 Headaches Diseases 0.000 description 4
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
• 206010021143 Hypoxia Diseases 0.000 description 4
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 4
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 4
• 108090001007 Interleukin-8 Proteins 0.000 description 4
• 102000004890 Interleukin-8 Human genes 0.000 description 4
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 4
• 206010041660 Splenomegaly Diseases 0.000 description 4
• 201000007201 aphasia Diseases 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 229940127089 cytotoxic agent Drugs 0.000 description 4
• 239000012634 fragment Substances 0.000 description 4
• 231100000869 headache Toxicity 0.000 description 4
• 230000007954 hypoxia Effects 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 210000005036 nerve Anatomy 0.000 description 4
• 208000035824 paresthesia Diseases 0.000 description 4
• JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 4
• NDSDGUULXHNXGA-RPDRRWSUSA-N (1r,2s)-1-[(6r)-2,4-diamino-5,6,7,8-tetrahydropteridin-6-yl]propane-1,2-diol Chemical group NC1=NC(N)=C2N[C@@H]([C@@H](O)[C@@H](O)C)CNC2=N1 NDSDGUULXHNXGA-RPDRRWSUSA-N 0.000 description 3
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical group C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 3
• ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 description 3
• MYQAUKPBNJWPIE-UHFFFAOYSA-N 5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine Chemical compound C1=CC(OC)=CC=C1COC(C(=C1)OC)=CC=C1CC1=CN=C(N)N=C1N MYQAUKPBNJWPIE-UHFFFAOYSA-N 0.000 description 3
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 102100032768 Complement receptor type 2 Human genes 0.000 description 3
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
• 206010012373 Depressed level of consciousness Diseases 0.000 description 3
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 3
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• 108010002616 Interleukin-5 Proteins 0.000 description 3
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 3
• 208000001647 Renal Insufficiency Diseases 0.000 description 3
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
• 229960001138 acetylsalicylic acid Drugs 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 229940124572 antihypotensive agent Drugs 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000036760 body temperature Effects 0.000 description 3
• 150000001886 cortisols Chemical class 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• 108010057085 cytokine receptors Proteins 0.000 description 3
• 230000013632 homeostatic process Effects 0.000 description 3
• 229960001680 ibuprofen Drugs 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 102000006495 integrins Human genes 0.000 description 3
• 108010044426 integrins Proteins 0.000 description 3
• 229940079322 interferon Drugs 0.000 description 3
• 201000006370 kidney failure Diseases 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000006724 microglial activation Effects 0.000 description 3
• 238000000386 microscopy Methods 0.000 description 3
• 230000000877 morphologic effect Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 229960005205 prednisolone Drugs 0.000 description 3
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
• 238000004393 prognosis Methods 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 230000035807 sensation Effects 0.000 description 3
• 231100000004 severe toxicity Toxicity 0.000 description 3
• 238000011301 standard therapy Methods 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 239000005526 vasoconstrictor agent Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• SHPFDGWALWEPGS-UHFFFAOYSA-N 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea Chemical compound COC1=CC(OC=2C3=CC(OC)=C(OC)C=C3N=CC=2)=CC=C1NC(=O)NC(C)C1=NC=CS1 SHPFDGWALWEPGS-UHFFFAOYSA-N 0.000 description 2
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
• NODCQQSEMCESEC-UHFFFAOYSA-N 5-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)-n-[[4-(trifluoromethyl)phenyl]methyl]pyridin-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=CC=C12 NODCQQSEMCESEC-UHFFFAOYSA-N 0.000 description 2
• GUBJNPWVIUFSTR-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CN(C(=O)CN(C)C)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 GUBJNPWVIUFSTR-UHFFFAOYSA-N 0.000 description 2
• 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
• 206010002961 Aplasia Diseases 0.000 description 2
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 108091008875 B cell receptors Proteins 0.000 description 2
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 description 2
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
• 206010012218 Delirium Diseases 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
• 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 2
• 101000653759 Homo sapiens Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 2
• 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
• FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 2
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
• 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 2
• 206010048294 Mental status changes Diseases 0.000 description 2
• 108091033773 MiR-155 Proteins 0.000 description 2
• 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 2
• 108010057466 NF-kappa B Proteins 0.000 description 2
• 102000003945 NF-kappa B Human genes 0.000 description 2
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
• 208000008457 Neurologic Manifestations Diseases 0.000 description 2
• 206010034580 Peripheral motor neuropathy Diseases 0.000 description 2
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
• 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
• 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 2
• 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 2
• 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 206010045170 Tumour lysis syndrome Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000000480 calcium channel blocker Substances 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 108700010039 chimeric receptor Proteins 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
• 150000001887 cortisones Chemical class 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 230000002559 cytogenic effect Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 229960000556 fingolimod Drugs 0.000 description 2
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 208000003906 hydrocephalus Diseases 0.000 description 2
• 229960001067 hydrocortisone acetate Drugs 0.000 description 2
• 229960002846 hydrocortisone probutate Drugs 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
• 229960004942 lenalidomide Drugs 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 238000012083 mass cytometry Methods 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 2
• 201000002239 motor neuritis Diseases 0.000 description 2
• 201000005545 motor peripheral neuropathy Diseases 0.000 description 2
• 229960004127 naloxone Drugs 0.000 description 2
• UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 230000003959 neuroinflammation Effects 0.000 description 2
• 229960000715 nimodipine Drugs 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 231100000862 numbness Toxicity 0.000 description 2
• 150000002926 oxygen Chemical class 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 150000003117 prednisolones Chemical class 0.000 description 2
• 150000003118 prednisones Chemical class 0.000 description 2
• 238000002203 pretreatment Methods 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 201000004193 respiratory failure Diseases 0.000 description 2
• 229960004181 riluzole Drugs 0.000 description 2
• 150000003873 salicylate salts Chemical class 0.000 description 2
• 238000011896 sensitive detection Methods 0.000 description 2
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 208000010380 tumor lysis syndrome Diseases 0.000 description 2
• 230000002227 vasoactive effect Effects 0.000 description 2
• IZIZKGZAEABSET-IEUZAGAGSA-N (1r,2s,6s,7r)-7-chloro-2-methyl-5-azabicyclo[4.1.0]hept-4-en-4-amine;hydrochloride Chemical compound Cl.C[C@H]1CC(=N)N[C@@H]2[C@H](Cl)[C@H]12 IZIZKGZAEABSET-IEUZAGAGSA-N 0.000 description 1
• YGCQFKVNIBDJFW-SFHVURJKSA-N (1s)-1-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol Chemical compound C1=CC=C2C(C[C@@H]3NCCC=4C=C(C(=CC=43)O)O)=CC=CC2=C1 YGCQFKVNIBDJFW-SFHVURJKSA-N 0.000 description 1
• NWBJAUFHPXRBKI-QMMMGPOBSA-N (2r)-2-amino-3-[2-(1-aminoethylideneamino)ethylsulfanyl]-2-methylpropanoic acid Chemical group CC(=N)NCCSC[C@](C)(N)C(O)=O NWBJAUFHPXRBKI-QMMMGPOBSA-N 0.000 description 1
• FTMJFHVKAXPFIY-UHFFFAOYSA-N 2,2-dichloro-N-[1,3-dihydroxy-1-(3-nitrophenyl)propan-2-yl]acetamide Chemical compound OCC(NC(=O)C(Cl)Cl)C(O)c1cccc(c1)[N+]([O-])=O FTMJFHVKAXPFIY-UHFFFAOYSA-N 0.000 description 1
• IRMTXMJNHRISQH-UHFFFAOYSA-N 2-[2-[2-(diaminomethylideneamino)ethyldisulfanyl]ethyl]guanidine Chemical compound NC(N)=NCCSSCCN=C(N)N IRMTXMJNHRISQH-UHFFFAOYSA-N 0.000 description 1
• IBHNEKVLDKCEQY-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical group C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(F)C=C1F IBHNEKVLDKCEQY-UHFFFAOYSA-N 0.000 description 1
• QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
• NMXIZJLIYYDNJG-UHFFFAOYSA-N 4-nitrooxybutyl 5-amino-2-hydroxybenzoate Chemical compound NC1=CC=C(O)C(C(=O)OCCCCO[N+]([O-])=O)=C1 NMXIZJLIYYDNJG-UHFFFAOYSA-N 0.000 description 1
• MVMKWLRKACAUTB-UHFFFAOYSA-N 5-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)-n-[[4-(trifluoromethyl)phenyl]methyl]pyridin-2-amine;dihydrochloride Chemical group Cl.Cl.C1=CC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=CC=C12 MVMKWLRKACAUTB-UHFFFAOYSA-N 0.000 description 1
• XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 description 1
• MVPKLZHNOLVZAU-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide;hydrochloride Chemical group Cl.C1CN(C(=O)CN(C)C)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 MVPKLZHNOLVZAU-UHFFFAOYSA-N 0.000 description 1
• VNGWBSXDGQZSFL-JMNKBGBLSA-N 6-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylcyclohex-3-ene-1-carboxylic acid Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)C1CC=CCC1C(O)=O VNGWBSXDGQZSFL-JMNKBGBLSA-N 0.000 description 1
• NSMOZFXKTHCPTQ-UHFFFAOYSA-N 6-fluoro-n-[(5-fluoro-2-methoxypyridin-3-yl)methyl]-5-[(5-methyl-1h-pyrrolo[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine Chemical compound COC1=NC=C(F)C=C1CNC(N=C1F)=CC=C1CC1=CNC2=NC=C(C)C=C12 NSMOZFXKTHCPTQ-UHFFFAOYSA-N 0.000 description 1
• DFMXJRGGNCRUHZ-UHFFFAOYSA-N 6h-isoquinolin-7-one Chemical compound C1=CN=CC2=CC(=O)CC=C21 DFMXJRGGNCRUHZ-UHFFFAOYSA-N 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000008190 Agammaglobulinemia Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
• 102100022749 Aminopeptidase N Human genes 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 101100273212 Arabidopsis thaliana CAR7 gene Proteins 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 208000007774 Broca Aphasia Diseases 0.000 description 1
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
• 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
• 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
• 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
• 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
• 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
• 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
• 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
• 108050007331 Cannabinoid receptor Proteins 0.000 description 1
• 201000005488 Capillary Leak Syndrome Diseases 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 206010048610 Cardiotoxicity Diseases 0.000 description 1
• 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
• 102000014464 Chemokine CX3CL1 Human genes 0.000 description 1
• UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
• 108091062157 Cis-regulatory element Proteins 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010013886 Dysaesthesia Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 206010014418 Electrolyte imbalance Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 208000009139 Gilbert Disease Diseases 0.000 description 1
• 208000022412 Gilbert syndrome Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019842 Hepatomegaly Diseases 0.000 description 1
• 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
• 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
• HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 1
• DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone cypionate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCC1CCCC1 DLVOSEUFIRPIRM-KAQKJVHQSA-N 0.000 description 1
• 208000004044 Hypesthesia Diseases 0.000 description 1
• 206010051125 Hypofibrinogenaemia Diseases 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 108010041012 Integrin alpha4 Proteins 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
• 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 102000003810 Interleukin-18 Human genes 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102000000704 Interleukin-7 Human genes 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 206010069360 Leukaemic infiltration Diseases 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 206010025102 Lung infiltration Diseases 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 206010025280 Lymphocytosis Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
• 208000004987 Macrophage activation syndrome Diseases 0.000 description 1
• MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
• 229940122938 MicroRNA inhibitor Drugs 0.000 description 1
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 101100005008 Mus musculus Ca7 gene Proteins 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 238000002944 PCR assay Methods 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
• SBQAKZYUNWNIRL-WIPKXTQKSA-N Prednisolone farnesylate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)/C=C(C)/CC/C=C(C)/CCC=C(C)C)(O)[C@@]1(C)C[C@@H]2O SBQAKZYUNWNIRL-WIPKXTQKSA-N 0.000 description 1
• HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 206010039203 Road traffic accident Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 108091005735 TGF-beta receptors Proteins 0.000 description 1
• 208000001871 Tachycardia Diseases 0.000 description 1
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 102000003929 Transaminases Human genes 0.000 description 1
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
• TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 1
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
• FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
• YZNQMPPBWQTLFJ-TUFAYURCSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CCC)(O)[C@@]1(C)C[C@@H]2O YZNQMPPBWQTLFJ-TUFAYURCSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 230000010398 acute inflammatory response Effects 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
• 238000007844 allele-specific PCR Methods 0.000 description 1
• 208000012759 altered mental status Diseases 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000010100 anticoagulation Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000005812 autoimmune toxicity Effects 0.000 description 1
• 231100001152 autoimmune toxicity Toxicity 0.000 description 1
• 231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 238000003287 bathing Methods 0.000 description 1
• 229950000210 beclometasone dipropionate Drugs 0.000 description 1
• 231100000871 behavioral problem Toxicity 0.000 description 1
• 229960002537 betamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
• PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
• 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
• 229960004311 betamethasone valerate Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 210000003969 blast cell Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 229950010831 cabiralizumab Drugs 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 229930003827 cannabinoid Natural products 0.000 description 1
• 239000003557 cannabinoid Substances 0.000 description 1
• 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 231100000259 cardiotoxicity Toxicity 0.000 description 1
• 230000007681 cardiovascular toxicity Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 229930002875 chlorophyll Natural products 0.000 description 1
• 235000019804 chlorophyll Nutrition 0.000 description 1
• ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
• 229960002688 choline salicylate Drugs 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000014514 chromosome 17p deletion Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229950009120 cindunistat Drugs 0.000 description 1
• 229960004703 clobetasol propionate Drugs 0.000 description 1
• CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
• 229960001357 clocortolone pivalate Drugs 0.000 description 1
• SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 231100000876 cognitive deterioration Toxicity 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 231100000870 cognitive problem Toxicity 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 231100000026 common toxicity Toxicity 0.000 description 1
• 231100000867 compulsive behavior Toxicity 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 150000001884 corticosterones Chemical class 0.000 description 1
• BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
• FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 1
• BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 208000024389 cytopenia Diseases 0.000 description 1
• 230000001120 cytoprotective effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000000779 depleting effect Effects 0.000 description 1
• 229960003657 dexamethasone acetate Drugs 0.000 description 1
• 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
• 229960002124 diflorasone diacetate Drugs 0.000 description 1
• FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 1
• 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
• 239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 1
• 229960004419 dimethyl fumarate Drugs 0.000 description 1
• 229940120889 dipyrone Drugs 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229950002507 elsilimomab Drugs 0.000 description 1
• 229950004647 emactuzumab Drugs 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 208000010771 expressive aphasia Diseases 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
• JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
• 229940042902 flumethasone pivalate Drugs 0.000 description 1
• 229960001347 fluocinolone acetonide Drugs 0.000 description 1
• FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
• 229960003336 fluorocortisol acetate Drugs 0.000 description 1
• 229960001629 fluorometholone acetate Drugs 0.000 description 1
• YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
• 229960003590 fluperolone Drugs 0.000 description 1
• HHPZZKDXAFJLOH-QZIXMDIESA-N fluperolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 description 1
• 229960000289 fluticasone propionate Drugs 0.000 description 1
• WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
• 231100001156 grade 3 toxicity Toxicity 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 208000011316 hemodynamic instability Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 206010019847 hepatosplenomegaly Diseases 0.000 description 1
• 231100000171 higher toxicity Toxicity 0.000 description 1
• 229960002453 hydrocortisone aceponate Drugs 0.000 description 1
• MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 description 1
• 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
• 229960003331 hydrocortisone cypionate Drugs 0.000 description 1
• 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
• 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
• 229950006240 hydrocortisone succinate Drugs 0.000 description 1
• 229960000631 hydrocortisone valerate Drugs 0.000 description 1
• 125000005350 hydroxycycloalkyl group Chemical group 0.000 description 1
• 208000034783 hypoesthesia Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000013394 immunophenotyping Methods 0.000 description 1
• 230000003116 impacting effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
• 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
• 229940100994 interleukin-7 Drugs 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 231100001106 life-threatening toxicity Toxicity 0.000 description 1
• 231100000861 limb weakness Toxicity 0.000 description 1
• 208000027905 limb weakness Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 235000014666 liquid concentrate Nutrition 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 231100000863 loss of memory Toxicity 0.000 description 1
• 231100000875 loss of motor control Toxicity 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
• 229960003744 loteprednol etabonate Drugs 0.000 description 1
• 208000030208 low-grade fever Diseases 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 229940072082 magnesium salicylate Drugs 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000005399 mechanical ventilation Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229960002037 methylprednisolone aceponate Drugs 0.000 description 1
• DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 description 1
• 229960001293 methylprednisolone acetate Drugs 0.000 description 1
• PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
• 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
• 229950009831 methylprednisolone succinate Drugs 0.000 description 1
• 108091056924 miR-124 stem-loop Proteins 0.000 description 1
• 239000002395 mineralocorticoid Substances 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• 229960002744 mometasone furoate Drugs 0.000 description 1
• WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• JUPOTOIJLKDAPF-UHFFFAOYSA-N n-[3-cyclopropyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C(C5CC5)=NN(CC=5N=C(C)C=CC=5)C=4C=CC=3)N2C=C1 JUPOTOIJLKDAPF-UHFFFAOYSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229960000965 nimesulide Drugs 0.000 description 1
• HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 229950010006 olokizumab Drugs 0.000 description 1
• 239000003401 opiate antagonist Substances 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 229960000865 paramethasone acetate Drugs 0.000 description 1
• UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 229960005222 phenazone Drugs 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
• 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 238000002616 plasmapheresis Methods 0.000 description 1
• 229960002800 prednisolone acetate Drugs 0.000 description 1
• 229950011084 prednisolone farnesylate Drugs 0.000 description 1
• JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
• 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
• 229950010987 prednisolone steaglate Drugs 0.000 description 1
• RBJROVWIRLFZFC-PNLFXGMVSA-N prednisolone steaglate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)COC(=O)CCCCCCCCCCCCCCCCC)(O)[C@@]1(C)C[C@@H]2O RBJROVWIRLFZFC-PNLFXGMVSA-N 0.000 description 1
• 229950004597 prednisolone succinate Drugs 0.000 description 1
• APGDTXUMTIZLCJ-CGVGKPPMSA-N prednisolone succinate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 APGDTXUMTIZLCJ-CGVGKPPMSA-N 0.000 description 1
• 229960004259 prednisolone tebutate Drugs 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 230000009325 pulmonary function Effects 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 208000037922 refractory disease Diseases 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229950008794 ronopterin Drugs 0.000 description 1
• 229950006348 sarilumab Drugs 0.000 description 1
• 238000009094 second-line therapy Methods 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 230000021317 sensory perception Effects 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 229950006094 sirukumab Drugs 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229960004249 sodium acetate Drugs 0.000 description 1
• 229940125794 sodium channel blocker Drugs 0.000 description 1
• 239000003195 sodium channel blocking agent Substances 0.000 description 1
• 229960004025 sodium salicylate Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 229940121136 tecfidera Drugs 0.000 description 1
• 229940072172 tetracycline antibiotic Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 230000007675 toxicity by organ Effects 0.000 description 1
• 231100000155 toxicity by organ Toxicity 0.000 description 1
• 238000002627 tracheal intubation Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 229960002117 triamcinolone acetonide Drugs 0.000 description 1
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
• DZQIYNZZUKIZNS-RCFDOMGHSA-N triamcinolone acetonide 21-palmitate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@@]1(C)C[C@@H]2O DZQIYNZZUKIZNS-RCFDOMGHSA-N 0.000 description 1
• 229950006782 triamcinolone benetonide Drugs 0.000 description 1
• GUYPYYARYIIWJZ-CYEPYHPTSA-N triamcinolone benetonide Chemical compound O=C([C@]12[C@H](OC(C)(C)O1)C[C@@H]1[C@@]2(C[C@H](O)[C@]2(F)[C@@]3(C)C=CC(=O)C=C3CC[C@H]21)C)COC(=O)C(C)CNC(=O)C1=CC=CC=C1 GUYPYYARYIIWJZ-CYEPYHPTSA-N 0.000 description 1
• 229960004320 triamcinolone diacetate Drugs 0.000 description 1
• 229960004221 triamcinolone hexacetonide Drugs 0.000 description 1
• 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
• 229940079023 tysabri Drugs 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• TVGAHWWPABTBCX-UHFFFAOYSA-N vimseltinib Chemical compound O=C1N(C)C(NC(C)C)=NC=C1C(N=C1C)=CC=C1OC1=CC=NC(C2=CN(C)N=C2)=C1 TVGAHWWPABTBCX-UHFFFAOYSA-N 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1